US equities |
MU $1,094.87 ▼-0.23% NVDA $236.75 ▲+2.55% SNDK $1,736.61 ▼-2.86% TSLA $370.85 ▲+4.73% STX $832.98 ▼-11.91% WDC $423.64 ▼-8.41% AMD $638.76 ▲+3.74% INTC $123.95 ▲+3.30%
FinancialContent

Biomea Fusion, Inc. - Common Stock (NQ:BMEA)

1.280 -0.020 (-1.54%)
Delayed Quote Updated: 9:43 AM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biomea Fusion, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Proposed Public Offering of Securities
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate in Upcoming Investor Conferences
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate at Upcoming Investor Conferences
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 Diabetes 
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate at Upcoming Investor Conferences
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate at Jefferies London Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
Initial Clinical Data Expected in the First Half of 2026 
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Pricing of Public Offering of Securities
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Proposed Public Offering of Securities
From Biomea Fusion, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >